Gilead And Bukwang End Licensing Pact For Clevudine, Investigational Agent For Chronic Hepatitis B - Clevudine

[Guest guest]

June 25, 2003

Gilead And Bukwang End Licensing Pact For Clevudine, Investigational Agent

For Chronic Hepatitis B -2

[Dow and Company, Inc.]

Dow Business News via NewsEdge Corporation : FOSTER CITY, Calif. -(Dow

)- Gilead Sciences Inc. (GILD) is terminating a licensing agreement

that began in 1998 with Bukwang Pharm. Ind. Co. to develop and market

clevudine, a potential chronic hepatitis B drug in phase I/II development.

In a press release Tuesday, Gilead said it owes no further payments to

Bukwang. However, it will continue to meet ongoing obligations under the

agreement.

A spokeswoman was not immediately available to say what these obligations

entail.

The original agreement was entered by Bukwang and Triangle Pharmaceuticals,

which Gilead acquired in January. The termination of the licensing agreement

is effective Aug. 6.

Gilead shares recently traded on Nasdaq at $53.40, up 94 cents, or 1.8%, on

composite volume of 458,853 shares. Average daily volume is 3.9 million

shares.

Gilead is a biopharmaceutical company.

Company Web site: http://www.gilead.com

- Vogel; Dow Newswires; 201-938-5400 .TABLE

[Guest guest]

June 25, 2003

Gilead And Bukwang End Licensing Pact For Clevudine, Investigational Agent

For Chronic Hepatitis B -2

[Dow and Company, Inc.]

Dow Business News via NewsEdge Corporation : FOSTER CITY, Calif. -(Dow

)- Gilead Sciences Inc. (GILD) is terminating a licensing agreement

that began in 1998 with Bukwang Pharm. Ind. Co. to develop and market

clevudine, a potential chronic hepatitis B drug in phase I/II development.

In a press release Tuesday, Gilead said it owes no further payments to

Bukwang. However, it will continue to meet ongoing obligations under the

agreement.

A spokeswoman was not immediately available to say what these obligations

entail.

The original agreement was entered by Bukwang and Triangle Pharmaceuticals,

which Gilead acquired in January. The termination of the licensing agreement

is effective Aug. 6.

Gilead shares recently traded on Nasdaq at $53.40, up 94 cents, or 1.8%, on

composite volume of 458,853 shares. Average daily volume is 3.9 million

shares.

Gilead is a biopharmaceutical company.

Company Web site: http://www.gilead.com

- Vogel; Dow Newswires; 201-938-5400 .TABLE

[Guest guest]

June 25, 2003

Gilead And Bukwang End Licensing Pact For Clevudine, Investigational Agent

For Chronic Hepatitis B -2

[Dow and Company, Inc.]

Dow Business News via NewsEdge Corporation : FOSTER CITY, Calif. -(Dow

)- Gilead Sciences Inc. (GILD) is terminating a licensing agreement

that began in 1998 with Bukwang Pharm. Ind. Co. to develop and market

clevudine, a potential chronic hepatitis B drug in phase I/II development.

In a press release Tuesday, Gilead said it owes no further payments to

Bukwang. However, it will continue to meet ongoing obligations under the

agreement.

A spokeswoman was not immediately available to say what these obligations

entail.

The original agreement was entered by Bukwang and Triangle Pharmaceuticals,

which Gilead acquired in January. The termination of the licensing agreement

is effective Aug. 6.

Gilead shares recently traded on Nasdaq at $53.40, up 94 cents, or 1.8%, on

composite volume of 458,853 shares. Average daily volume is 3.9 million

shares.

Gilead is a biopharmaceutical company.

Company Web site: http://www.gilead.com

- Vogel; Dow Newswires; 201-938-5400 .TABLE

[Guest guest]

June 25, 2003

Gilead And Bukwang End Licensing Pact For Clevudine, Investigational Agent

For Chronic Hepatitis B -2

[Dow and Company, Inc.]

Dow Business News via NewsEdge Corporation : FOSTER CITY, Calif. -(Dow

)- Gilead Sciences Inc. (GILD) is terminating a licensing agreement

that began in 1998 with Bukwang Pharm. Ind. Co. to develop and market

clevudine, a potential chronic hepatitis B drug in phase I/II development.

In a press release Tuesday, Gilead said it owes no further payments to

Bukwang. However, it will continue to meet ongoing obligations under the

agreement.

A spokeswoman was not immediately available to say what these obligations

entail.

The original agreement was entered by Bukwang and Triangle Pharmaceuticals,

which Gilead acquired in January. The termination of the licensing agreement

is effective Aug. 6.

Gilead shares recently traded on Nasdaq at $53.40, up 94 cents, or 1.8%, on

composite volume of 458,853 shares. Average daily volume is 3.9 million

shares.

Gilead is a biopharmaceutical company.

Company Web site: http://www.gilead.com

- Vogel; Dow Newswires; 201-938-5400 .TABLE